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ABSTRAK
Latar belakang: sarkopenia berkontribusi terhadap terjadinya sindrom frailty. Sindrom frailty berpotensi 
membaik dengan memodifikasi faktor inflamasi, resistensi insulin, dan miostatin. Penelitian ini bertujuan 
mempelajari pengaruh metformin terhadap kekuatan genggam tangan, kecepatan berjalan, konsentrasi miostatin 
serum, dan kualitas hidup terkait kesehatan pada pasien lanjut usia (lansia) non-diabetes dengan pre-frail. 
Metode: studi ini merupakan uji klinis acak tersamar ganda yang dilakukan pada pasien rawat jalan berusia 
≥ 60 tahun dengan status pre-frail berdasarkan kriteria fenotip dan/atau indeks (Cardiovascular Health Study dan/
atau Frailty Index 40 items) di Rumah Sakit Cipto Mangunkusumo yang direkrut dari bulan Maret 2015 sampai 
Juni 2016. Subjek yang memenuhi kriteria penelitian dirandomisasi menjadi grup metformin (3 x 500 mg) atau 
grup plasebo (amilum 3 x 500 mg). Luaran penelitian diukur pada awal studi dan 16 minggu setelah intervensi. 
Hasil: dari 120 subjek, 43 subjek dari grup metformin dan 48 subjek dari grup plasebo yang menyelesaikan 
penelitian. Terdapat peningkatan kecepatan berjalan pada kelompok metformin sebesar 0,39 (0,77) detik atau 
0,13 (0,24) meter/detik yang tetap bermakna setelah disesuaikan dengan faktor prognostik penting (p=0,024). 
Tidak didapatkan perbedaan bermakna kekuatan genggam tangan, konsentrasi miostatin serum, dan kualitas 
hidup terkait kesehatan antara kedua kelompok perlakuan. Kesimpulan: pemberian metformin 3 x 500 mg 
selama 16 minggu secara bermakna meningkatkan kecepatan berjalan sebagai salah satu dimensi kualitas 
hidup terkait kesehatan, namun tidak meningkatkan secara bermakna skor indeks EQ-5D, kekuatan genggam 
tangan, dan konsentrasi miostatin serum. 
Kata kunci: kecepatan berjalan, kekuatan genggam tangan, kualitas hidup, metformin, miostatin, pre-frail, 
lanjut usia.
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ABSTRACT
Background: sarcopenia contributes to the development of frailty syndrome. Frailty syndrome is potentially 
improved by modifying insulin resistance, inflammation, and myostatin level. This study is aimed to investigate 
the effect of metformin on handgrip strength, gait speed, myostatin serum level, and health-related quality of life 
(HR-QoL) among non-diabetic pre-frail elderly patients. Methods: a double blind randomized controlled trial 
was conducted on non-diabetic elderly outpatients aged ≥ 60 years with pre-frail status based on phenotype 
and/ or index criteria (Cardiovascular Health Study and/ or Frailty Index 40 items) consecutively recruited 
from March 2015 to June 2016 at Cipto Mangunkusumo Hospital. One-hundred-twenty subjects who met the 
research criteria were randomized and equally assigned into 3 x 500 mg metformin or placebo group. The 
study outcomes were measured at baseline and after 16 weeks of intervention. Results: out of 120 subjects, 43 
subjects in metformin group and 48 subjects in placebo group completed the intervention. There was a significant 
improvement on the mean gait speed of metformin group by 0.39 (0.77) second or 0.13 (0.24) meter/second 
that remained significant after adjusting for important prognostic factors (p = 0.024). There was no significant 
difference on handgrip strength, myostatin serum level, and HR-QoL between both groups. Conclusion: 3 x 
500 mg metformin for 16 weeks was statistically significant and clinically important in improving usual gait 
speed as one of the HR-QoL dimensions, but did not significantly improve the EQ-5D index score, handgrip 
strength, nor myostatin serum level.
Keywords: elderly, gait speed, handgrip strength, health-related quality of life, metformin, myostatin serum, 
pre-frail.
INTRODUCTION
Sarcopenia, a progressive loss of muscle 
mass and function with advancing age, leads to 
decreased metabolic rate, muscle strength, and 
maximal VO2 resulting in clinical/ phenotypic 
manifestations of frailty syndrome (i.e. physical 
frailty) that is characterized by weight loss, 
exhaustion, weakness, slowness, and low 
physical activity level.1 Sarcopenia is considered 
to be related to myostatin, a transforming growth 
factor-β (TGF-β) that trigger muscle protein 
degradation which leads to muscle growth 
inhibition.2,3
Frailty syndrome is a continuum spectrum 
of normal/ robust, pre-frail, and frail states 
with dynamic transition from robustness to 
frailer state and vice versa.4 Inflammation, 
insulin resistance, diabetes mellitus (DM), 
low vitamin D concentration and protein 
intake, poly-pharmacy (> 4 medications), and 
depression have significant association with the 
incidence of frailty syndrome.5–11 Administration 
of metformin potentially improves frailty 
syndrome by modifying insulin resistance, 
hyperglycemia, inflammation, and myostatin 
level. Not only does metformin activate cellular 
metabolic Adenosine Monophosphate-Activated 
Protein Kinase (AMPK), it also inhibits Nuclear 
Factor-ĸB (NF-ĸB) and mammalian Target 
of Rapamycin (mTOR).12–14 Metformin also 
improves Na+K+ATPase activity and increases 
circulating nitric oxide which optimize cellular 
energy production.15 On the other hand, previous 
studies indicated that AMPK may trigger muscle 
protein degradation and down-regulate muscle 
protein synthesis by stimulating myostatin 
expression and mTOR signal.16,17
Bulcao et al18 study showed that 16-weeks 
administration of 2 x 850 mg metformin for 
pre-diabetic subjects significantly decreased 
body mass index (BMI), inflammation mediators 
(C-reactive protein/ CRP and interleukin-6/ IL-
6), and fasting blood glucose as well as improved 
insulin resistance (evaluated by HOMA IR). 
Esteghamati et al19 reported that administration 
of 1000 mg metformin/day for 12 weeks in 
newly diagnosed type-2 diabetes mellitus (DM) 
patients significantly improved oxidative stress. 
Furthermore, previous in vitro study showed that 
metformin increased the myostatin expression 
and myostatin protein level in C2C12 myotubes 
at low concentration (0.5 mM), but down-
regulated them at higher concentration (1.5 and 
2.0 mM).17
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A case-control study indicated the protective 
effect of metformin against frailty syndrome. 
This study showed significant difference of 
frailty status between metformin-treated and 
non-metformin-treated type-2 DM patients.20 
However, there is no randomized, double 
blind, clinical trial on the effect of metformin 
on frailty syndrome, especially its effect on 
physical components of frailty syndrome and 
myostatin serum level. The aim of this study was 
to investigate the effects of metformin with the 
dose of 500 mg three times daily for 16 weeks on 
handgrip strength, gait speed, myostatin serum 
level, and health-related quality of life (HR-
QoL) among non-diabetic pre-frail elderly. To 
the best of authors’ knowledge, this was the first 
study that investigated the effect of metformin 
administration in order to prevent physical 
frailty in non-diabetic pre-frail elderly. It was 
also the first study that investigated the effect of 
metformin on myostatin serum level in human.
METHODS
This was a double blind randomized 
controlled trial. Subjects were allocated in 
each treatment group using permuted block 
randomization with block size of four and the 
code lists were concealed. Investigators, doctors, 
and subjects were blinded to treatment allocation 
(double blind).
Study Participants
Elderly outpatients aged 60 years and older 
with pre-frail status based on Cardiovascular 
Health Study (CHS)1 and/ or Frailty Index 40 
items (FI 40 items) score,21 were consecutively 
recruited from March 2015 to June 2016 at 
Geriatric and Internal Medicine Clinic in Cipto 
Mangunkusumo Hospital, Jakarta, Indonesia. 
Exclusion criteria were unwillingness to 
participate in this study, malnutrition (body mass 
index/ BMI < 18.5 kg/m2 or Mini Nutritional 
Assessment/ MNA full form score < 17), diabetes 
mellitus, cognitive impairment (Abbreviated 
Mental Test/AMT score < 8), depression 
(Geriatric Depression Scale/ GDS score ≥ 10), 
acute phase of disease(s), and contraindication(s) 
to metformin. The minimum sample size for gait 
speed outcome was 29 subjects, whereas for 
handgrip strength, myostatin serum level, and 
HR-QoL outcomes were 60 subjects for each 
treatment group.
Intervention Protocol
After giving written consent, eligible 
subjects were randomly assigned to metformin 
(3 x 500 mg) or placebo (amylum 3 x 500 
mg) group for 16 weeks of intervention. Both 
metformin and placebo capsules prepared by the 
hospital’s pharmacy unit were indistinguishable. 
The allocated treatment was dispensed to the 
subjects every four weeks.
The collected data consist of subjects’ 
demographic data (age, sex, income, level 
of education), clinical data (illnesses and 
medications history), functional status (Barthel 
index Basic Activity of Daily Living/ B-ADL and 
Lawton Instrumental Activity of Daily Living/ 
L-IADL), mental status (GDS), cognitive status 
(AMT), frailty status (CHS and FI 40 items), 
level of activities (Physical Activity Scale for 
the Elderly/ PASE), sarcopenia status (Asian 
Working Group of Sarcopenia/AWGS criteria),22 
anthropometry measurements, nutritional 
status (MNA full form as well as food record 
of two weekdays and one holiday), and body 
composition (Bioelectrical Impedance Analysis/ 
BIA Tahita SC 330). Fasting venous blood 
samples were collected for myostatin serum 
level, oral glucose tolerance test (OGTT) as well 
as liver and renal function test.
The measurement of study outcomes was 
conducted at baseline and after 16 weeks of 
intervention. Handgrip strength of dominant hand 
was assessed using JAMAR hydraulic handheld 
dynamometer model J00105 and was conducted 
in accordance with American Society of Hand 
Therapist (ASHT) recommended procedure.23 
The 15-feet walk test was performed to measure 
usual gait speed. Myostatin serum level was 
measured using ELISA kit Immundiagnostik 
AG, Bensheim, Germany Cat #K1012. Health-
related quality of life was assessed using 
Euro Quality of life-5 Dimensions (EQ-5D) 
questionnaire with 3 Likert scale. Adverse 
events, drug’s side effects, compliance, level of 
activities, consumption of other medications, and 
co-morbidities were evaluated every four weeks. 
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Ethics
This study was approved by the Ethical 
Committee of Faculty of Medicine Universitas 
Indonesia/ Cipto Mangunkusumo Hospital 
(No. 69/UN2.F1/ETIK/2015) and registered in 
clinical trial database www.clinicaltrials.gov 
with identifier number NCT02325245. The study 
procedure was performed in accordance with the 
Helsinki, Guideline for Good Clinical Practice 
from ICH Tripartite Guideline (ICH-GCP).
Statistical Analysis
Data analysis were done using SPSS 20. 
Drop-out subjects were excluded from the 
analyses (per protocol analysis). Intention-to-
treat (ITT) analysis was used to estimate the 
treatment’s efficacy in order to get the number 
needed-to-treat (NTT). Ancova statistic test was 
used to analyze the study outcomes of the two 
assigned groups, since some important prognostic 
factors of the baseline subjects’ characteristics 
(including numerical and categorical data) were 
unequal.
RESULTS
Despite recruiting 153 elderly patients to 
participate in the study, as many as 33 subjects 
were excluded from this clinical trial (of which 
16 patients declined to participate and 17 did 
not meet the research criteria) which resulted in 
120 subject who were randomized and equally 
assigned into metformin or placebo group (60 
subjects in each group). There were 43 subjects 
in metformin group and 48 subjects in placebo 
group who completed the intervention (Figure 1).
From 91 subjects who completed the 
intervention, the mean age was 68.97 (5.34) 
years old and more than half (62.64%) were 
female. The top four co-morbidities in both 
groups were hypertension, dyslipidemia, knee 
osteoarthritis (OA), and stable coronary artery 
disease. There was no subject with sarcopenia 
based on AWGS criteria. Compared to subjects 
in placebo group, subjects in metformin group 
were less likely to have dyslipidemia, knee 
OA, and CIRS score >5, but more likely to be 
Enrollment:
Assessed for eligibility (n = 153)
Excluded (n = 33)
 did not meet inclusion criteria (n = 17)
 declined to participate (n = 16)
 other reasons (n = 0)
Analyzed (n = 43)
 Lost to follow-up (reason: death) (n = 1)
 Discontinued intervention (n = 16), reasons:
2 poor compliances, 14 drug adverse effects
Allocated to metformin (n = 60)
 Lost to follow-up (n = 0)
 Discontinued intervention (n = 12), reasons:
7 poor compliances, 5 drug adverse effects
Allocated to placebo (n = 60)
Analyzed (n = 48)
Randomized (n = 120)
Figure 1. Flow diagram of randomized clinical trial
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younger, consume acetylsalicylic acid (ASA), 
as well as to have higher fat mass, BMI, upper 
arm muscle circumference, calf circumference, 
skeletal muscle index, and handgrip strength 
(Table 1 and Table 2).
Table 1. Baseline demographic characteristic of the 
subjects
Characteristics
Metformin 
(n=43)
Placebo 
(n=48)
Age (years), median 
(min–max) 67.77 (5.14) 70.04 (5.34)
Sex, n (%)  
 - Female 24 (55.8) 33 (68.8)
 - Male 19 (44.2) 15 (31.2)
Level of Education, n (%)
 - Low 3 (7) 5 (10.4)
 - Moderate 10 (23.2) 13 (27.1)
 - High 30 (69.8) 30 (62.5)
Co-morbidity, n (%)
 - Hypertension 38 (88.4) 39 (81.3)
 - Dyslipidemia 24 (55.8) 37 (77.1)
 - Knee osteoarthritis 23 (53.5) 30 (62.5)
 - Coronary artery 
disease 17 (39.5) 11 (22.9)
CIRS score, n (%)
 - ≤ 5 22 (51.2) 17 (35.4)
 - > 5 21 (48.8) 31 (64.6)
Poly-pharmacy, n (%)      
 - Yes 31 (72.1) 38 (79.2)
 - No 12 (27.9) 10 (20.8)
Medications used, n (%)
 - Statin 36 (83.7) 42 (87.5)
 - Proton pump inhibitor 
(PPI) 25 (58.1) 31 (64.6)
 - Angiotensin receptor 
blocker (ARB) 28 (65.1) 24 (50)
 - Acetylsalicylic acid 
(ASA) 24 (55.8) 13 (27.1)
 - Calcium-vitamin D 
supplement 9 (20.9) 16 (33.3)
 - ACE inhibitor 5 (11.6) 7 (14.6)
Table 3 shows that the baseline mean 
walking time in metformin group was 4.05 (0.93) 
seconds which represented the mean usual gait 
speed of 1.18 (0.26) meter/second, whereas the 
mean walking time in placebo group was 4.29 
(1.38) seconds which represented the mean usual 
gait speed of 1.14 (0.26) meter/second. The 
Table 2. Baseline characteristic of subjects’ nutritional 
status parameter
Characteristics
Metformin 
(n=43)
Placebo 
(n=48)
Anthropometry Measurements, mean (SD) 
Mid-arm circumference 
(cm) 31.65 (3.3) 28.35 (2.93)
 - Male 30.08 (2.98) 28.00 (3.09)
 - Female 32.89 (3.06) 28.51 (2.88)
Upper-arm Muscle 
Circumference (cm) 24.37 (2.33) 22.41 (1.88)
 - Male 24.79 (2.54) 22.73 (1.40)
 - Female 24.09 (2.15) 22.27 (2.07)
Waist circumference 
(cm) 94.44 (9.56) 87.35 (9.71)
 - Male 93.23 (10.24) 88.02 (11.35)
 - Female 95.39 (9.09) 87.05 (9.04)
Thigh circumference 
(cm) 51.88 (4.35) 46.95 (4.69)
 - Male 50.44 (4.57) 46.46 (3.44)
 - Female 53.00 (3.89) 47.17 (5.19)
Calf circumference (cm) 37.22 (3,20) 34.74 (3.90)
 - Male 36.76 (2,78) 35.87 (3.67)
 - Female 37.59 (3,51) 34.22 (3.93)
BMI (kg/m2) 27.40 (3.15) 23.90 (3.10)
 - Male 26.17 (3.28) 23.91 (2.85)
 - Female 28.37 (2.73) 23.90 (3.25)
Body composition
Muscle mass (kg), 
median (min–max)
39.8  
(34.0–62.8)
37.4  
(29.3–59.7)
Muscle mass Index 
(kg/m2), median (min-
max)
16.23  
(14.69–20.35)
15.42  
(12.77–20.66)
 - Male, mean (SD) 18.89 (1.38) 18.14 (1.19)
 - Female, mean (SD) 15.79 (0.51) 14.79 (0.97)
Fat Mass (kg), mean 
(SD) 22.92 (8.25) 17.63 (6.81)
 - Male 16.52 (6.32) 13.16 (5.13)
 - Female 27.99 (5.7) 19.66 (6.55)
Dietary Intake
Energy (Kcal), mean 
(SD)
1,434.60 
(320.87)
1,418.27 
(265.32)
Protein (gram), mean 
(SD) 47.53 (11.80) 46.56 (12.09)
Vitamin D (mcg), 
median (min–max)
4.3  
(0.1–20.8)
2.8  
(0.1–17.10)
Calcium (mg), median 
(min–max)
304.5  
(66.3-2,451.5)
372.25  
(79.7–2,848.7)
OGTT, mean (SD)
Fasting (mg/dL) 89.47 (9.26) 88.81 (8.85)
Post 75 gr glucose load 
(mg/dL)
127.67 
(30.48)
136.31 
(30.68)
Pre-diabetes, n (%) 18 (41.9) 21 (43.8)
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baseline median handgrip strength in metformin 
group was 24 (12–45) kg, whereas in placebo 
group was 20 (14–38) kg. The baseline median 
myostatin serum level of all subjects was 35.26 
(17.77–133.95) ng/mL. The baseline median 
EQ-5D index score in metformin group was 
0.77 (0.57–1.0) with EQ-5D VAS score of 80 
(40–90), whereas the median EQ-5D index score 
in placebo group was 0.77 (0.59–1.0) with EQ-
5D VAS score of 75 (48–100). The compliance 
rate of both groups was good, which was 91.05 
(5.67)% in metformin group and 91.74 (5.96)% 
in placebo group.
Ancova statistic test showed that at the end 
of intervention there was a significant difference 
in usual gait speed between metformin and 
placebo group, which remained statistically 
significant even after adjusting for age, sex, knee 
OA, acetylsalicylic acid consumption, as well as 
baseline handgrip strength, calf circumference, 
and BMI (Table 4). The mean walking time in 
metformin group became 0.39 (0.77) seconds 
shorter than baseline. In other words, there was 
a significant improvement on usual gait speed 
by 0.13 (0.24) meter/second.
Although there was a significant difference 
in handgrip strength between metformin 
and placebo group in unadjusted model, the 
difference was statistically insignificant after 
adjusting for important prognostic factors. 
Moreover, there were also no significant 
difference in myostatin serum level and HR-QoL 
between the two groups (Table 4). 
Until the end of intervention, the dietary 
intake as well as physical activity level of the 
Table 3. Baseline characteristics of subjects’ level of 
activity, frailty status, and study outcomes
Characteristics
Metformin 
(n=43)
Placebo 
(n=48)
B-ADL Score, n (%)
 - Independence 38 (88.4) 43 (89.6)
 - Mild Dependency 5 (11.6) 5 (10.4)
PASE Score (Kcal 
per week), mean 
(SD)
1,200.69 
(619.11)
1,206.82 
(585.71)
FI 40 items score, 
mean (SD) 0.147 (0.040) 0.151 (0.040)
Handgrip strength 
(kg), med (min–
max)
24 (12–45) 20 (14–38)
 - Male, mean (SD) 32.53 (5.65) 27.27 (5.00)
 - Female, median 
(min–max) 20 (12–26) 18 (14–38)
Walking Time 
(second), mean 
(SD)
4.05 (0.93) 4.29 (1.38)
 - Male 3.68 (0.78) 3.79 (0.69)
 - Female 4.35 (0.94) 4.52 (1.56)
Gait Speed (meter/
second), mean (SD) 1.18 (0.26) 1.14 (0.26)
 - Male 1.29 (0.25) 1.24 (0.23)
 - Female 1.10 (0.25) 1.09 (0.27)
Myostatin Serum 
Level (ng/mL), 
median (min–max)
35.72  
(17.77–56.85)
34.83  
(18.33–133.95)
Health-Related 
Quality of Life: 
EQ-5D Index Score, 
median (min–max)
0.77 
(0.57–1.0)
0,77  
(0.59–1.0)
Health-Related 
Quality of Life: 
EQ-5D VAS Score, 
median (min–max)
80 (40–90) 75 (48–100)
Drug compliance (%), 
mean (SD) 91.05 (5.67) 91.74 (5.96)
Table 4. The effect of metformin on handgrip strength, walking time, myostatin serum level, and health-related quality of life
Study Outcomes
Unadjusted
p
Adjusted∞
pMetformin Placebo Metformin Placebo
mean (95%CI) mean (95%CI) mean (95%CI) mean (95%CI)
Handgrip Strength (kg) 25.47  (23.51–27.42)
21.90  
(20.04–23.75) 0.010
23.39  
(22.28–24.49)
23.50  
(22.57–24.44) 0.877
Walking Time (second) 3.66  (3.32–3.99)
4.25  
(3.94–4.57) 0.012
3.72  
(3.37–4.06)
4.23  
(3.94–4.52) 0.024
Myostatin Serum Level (ng/
mL)
35.77  
(32.65–38.89)
36.58  
(33.62–39.53) 0.711
34.82  
(31.69–37.95)
37.43  
(34.48–40.38) 0.244
EQ-5D Index Score 0.83  (0.79–0.87)
0.82  
(0.78–0.86) 0.761
0.85  
(0.80–0.89)
0.83  
(0.79–0.87) 0.660
∞ Ancova Test
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metformin and placebo group were similar (data 
not shown). Gastrointestinal symptoms, such as 
diarrhea, nausea, bloated, and epigastric pain 
were the side effects of metformin commonly 
reported in this study. There were five serious 
adverse events (SAEs) in metformin group: 
death after heart attack, recurrent stroke, 
malleolus ulcers, diarrhea, and melena.
DISCUSSION
According to the AWGS criteria, the median 
handgrip strength in both intervention groups 
were within normal limit. Similarly, the mean 
usual gait speed of both groups were also good, 
which were above 1 meter/second.22
At the end of intervention, the mean walking 
time in metformin group improved significantly 
by 0.39 (0.77) seconds which represented the 
mean gait speed improvement by 0.13 (0.24) 
meter/second. This finding is consistent with 
Lee et al24 cohort study which reported that the 
decrease in gait speed among diabetic patients 
who received insulin sensitizer drugs (metformin 
or thiazolidinedione) was not only lesser than 
diabetic patients who received other types of 
oral anti-diabetic drugs but also lesser than non-
diabetic patients.
Previous study indicated that the minimum 
improvement of gait speed by 0.05 meter/second 
is considered significant, whereas a 0.10 meter/
second change in gait speed is considered a 
substantial improvement.25 The age-adjusted 
relative risk ratio per 0.1 meter/second greater 
speed for B-ADL dependence was 0.68 (95%CI 
0.57–0.81) among male and 0.74 (95%CI 
0.66–0.82) among female.26 Every 0.1 meter/
second decrease in gait speed was also associated 
with a 7% increase in risk for falls.27 Meta-
analysis of 9 cohorts concluded that gait speed 
was associated with survival with pooled HR 
0.88 (95%CI 0.87–0.90) per 0.1 meter/second 
improvement.28 Hence, the 0.13 (0.24) meter/
second improvement of usual gait speed found 
in our study was not only statistically significant 
but also clinically important.
Insulin resistance state decreases muscle 
mass and muscle contractility due to cytokine, 
increased myostatin expressions, and ineffective 
insulin activity which result in reduction of blood 
flow and skeletal muscle glucose uptake, as well 
as muscle protein degradation.17,29 Kuo et al30 
study reported that among non-diabetic elderly 
patients, every 1 standar deviation increment of 
HOMA-IR value was parallel with a decrease in 
gait speed of 0.04 meter/second (p=0.003). The 
significant gait speed improvement in metformin 
group might be caused by the improvement in 
insulin resistance state, inflammation, oxidative 
stress, and nitric oxide. Our study did not assess 
the laboratory parameter of inflammation nor 
insulin resistance. However, the significant 
decrease in BMI and waist circumference among 
subjects in metformin group (data not shown) 
might represent the improvement in their insulin 
resistance state.
Our study showed that handgrip strength was 
not a suitable parameter to investigate the effects 
of metformin. The purpose of handgrip strength 
measurement is to evaluate the isometric hand 
muscle contraction which is a sudden, fast, and 
high force activity. The muscle fibers that are 
particularly involved in this kind of activity are 
type-II muscle fiber (fast twitch) whose source 
of energy comes from anaerobic metabolism 
of ATP and creatine phosphate stored in the 
muscle.31,32 It seems that metformin has no 
important role in the utilization of stored ATP 
and creatine phosphate to produce that kind of 
energy. Furthermore, metformin was not found 
to increase muscle mass (data not shown), thus 
the stored ATP and creatine phosphate in the 
muscle which are parallel with higher muscle 
mass was probably not elevated.
In contrast to handgrip strength test, the 15-
feet (~4.57 meter) walking test is a dynamic, 
constant, and rhythmic muscle contraction 
without inflicted fatigue on oxygen transport 
system. The source of energy for this kind of 
activity may not only derive from anaerobic 
metabolism of creatinine phosphate, but also 
from glycogen and glucose aerobic metabolism. 
Metformin administration increases the glucose 
and calcium uptake of the skeletal muscle by 
improving the insulin resistant state.13,29,32,33 
Therefore, gait speed improvement occurred in the 
metformin group. However, further investigation 
on the mechanism of how metformin improves 
gait speed is needed, especially regarding the 
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muscle energy metabolism.
Intention-to-treat analysis on the absence 
or presence of increased gait speed of > 
0.1 meter/second showed that there were 
40 events out of 60 subjects (66.7%) in the 
metformin group and 45 events out of 60 
subjects (75%) in the placebo group. Absolute 
risk reduction (ARR) was 8.3% (95%CI 
-7.9–24%; p = 0.422) which resulted in NNT of 
12. It was suggested that the administration of 
metformin to 12 pre-frail elderly patients was 
needed to add one gait speed improvement of 
> 0.1 meter/second.
The myostatin serum levels in this study 
was higher than what was reported in Ryan 
et al34 study but almost similar to the mean 
plasma myostatin level in Hittel et al35 study. 
The varying results in myostatin serum/ plasma 
level among studies are assumed to be related to 
distinct ELISA assays of different antigen and 
antibody combinations with variances in the 
sensitivity and specificity, whether it measures 
both the mature active C-terminal dimer of 
myostatin and the N-terminal propeptide or 
it specifically measures the active C-terminal 
dimer. Moreover, the mean and higher proportion 
body mass index of our subjects were classified 
as overweight–obese (based on Asia-Pacific 
criteria36) and 42.9% of the subjects were in pre-
diabetic state. It has been reported that mRNA 
myostatin expression in muscle and serum/ 
plasma myostatin level are increased in insulin 
resistant state and obesity.2,3,35,37 Therefore, those 
factors also contributed to the higher myostatin 
serum level in our study.
At the end of observation, our study did 
not find significant difference in myostatin 
serum level between metformin and placebo 
group. There was also no significant difference 
in myostatin serum level before and after 
intervention among subjects in metformin group. 
Previous in vitro study showed inconclusive 
result whether metformin increases or decreases 
myostatin level.17 In contrast to our study, Ryan et 
al34 and Hittel et al35 reported that exercise, which 
is another AMPK activator, significantly affected 
myostatin serum/ plasma level. However, those 
studies were not randomized controlled trials.
Myostatin level can be evaluated by 
measuring its concentration in serum or plasma 
and detecting mRNA expression of myostatin 
in muscle. mRNA expression of myostatin in 
the muscle represents biological activity of 
myostatin in the body. Unfortunately, muscle 
biopsy to measure mRNA expression of 
myostatin was not conducted in our clinical trial. 
Furthermore, changes in mRNA expression of 
myostatin in muscle are not always followed 
by changes in myostatin serum or plasma level. 
Brandt et al38 reported that although mRNA 
myostatin expressions in muscle were 1.4 times 
higher in type 2 DM subjects compared to normal 
subjects, there was no significant difference in 
plasma myostatin level between the two groups. 
Therefore, whether metformin affected mRNA 
expression of myostatin in skeletal muscle or 
not was still unknown.
The median score of EQ-5D index in our 
study was quite good since most subjects had 
good functional status with B-ADL score 
ranged 19–20 and our study excluded subjects 
with depression and cognitive impairment. 
Administration of metformin for 16 weeks 
did not show improvement in HR-QoL among 
elderly outpatients. It seems that metformin did 
not directly enhance the overall HR-QoL, but 
rather improved the mobility which is considered 
as one of the many dimensions of HR-QoL. In 
the future, improvement in mobility is expected 
to increase patient’s capability in daily life 
activities.
Out of 17 subjects in the metformin group 
who drop-out, 14 subjects experienced the 
adverse effects of metformin, 1 subject died, 
and 2 subjects had poor compliance. In placebo 
group, there were 5 drop-out subjects due to drug 
adverse effects and 7 drop-out subjects due to 
poor compliance. The number needed to harm 
(NNH) was -12, which indicated that subjects in 
the placebo group had fewer risk of experiencing 
adverse effects compared to metformin group. 
However, this NNH value did not seem to 
represent the NNH of metformin in daily clinical 
practice which has been widely used as the first 
line treatment for type 2 DM. Subject drop 
out due to gastrointestinal symptoms occurred 
mostly in the first week of the intervention. 
Although re-education and counselling had been 
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re-applied to them, those subjects still refused to 
continue the study. A review by Scheen et al39 
suggested that the elderly have relatively good 
tolerance to metformin and its safety is more 
related to the documented contraindications 
rather than age per se.
Although there were five serious adverse 
events (SAEs) reported in the metformin group 
(e.g. death after heart attack, recurrent stroke, 
malleolus ulcers, diarrhea, and melena), further 
investigation showed that all of those subjects 
had initially possessed the risk factors for those 
events. Therefore, it can be concluded that SAEs 
were not related to metformin administration.
There were several limitations of this study. 
The proportion of drop-out subjects was 24% 
due to drug side effects, poor compliance, and 
death. However, the important prognostic factors 
of the subjects who completed the study were 
similar to those drop-out subjects.
The data analysis can only be applied to 
those who completed the study (per protocol 
analysis). However, due to logistic limitations, 
despite the prolonged subjects’ recruitment 
period for 15 months, this study did not meet 
the minimum sample size of 60 subjects who 
completed the study in each treatment group. 
Nevertheless, the minimum sample size for the 
study outcome on gait speed was already met, 
which was a minimum of 29 subjects in each 
treatment group. Therefore, the result analysis 
for gait speed was valid and has good statistical 
power (80%).
Objective measurement of insulin resistance 
and inflammation mediators, as well as 
measurement of lower extremities strength 
were not conducted in this study. Therefore, 
this study cannot fully explain the mechanism 
of metformin in improving the study outcome. 
Muscle biopsy to evaluate the mRNA expression 
of myostatin was not conducted in this study. 
Hence, it remains undetermined whether 
metformin affected mRNA expression of 
myostatin in skeletal muscle or not. Moreover, 
the measurement of body composition in this 
study used BIA which is not as accurate as Dual-
Energy X-Ray Absorptiometry (DXA).
CONCLUSION
Our results suggested that administration 
of metformin with the dose of 3 x 500 mg for 
non-diabetic pre-frail elderly subjects for 16 
weeks was statistically significant and clinically 
important in improving usual gait speed, but it 
did not significantly increase handgrip strength 
nor decrease myostatin serum level. Although 
there was an improvement of mobility as one 
of HR-QoL dimensions, it did not increase the 
overall score of EQ-5D index.
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